Signaling Pathways - MAGL - DOT1L - Myosin light chain kinases (MLCKs) - FGFR
清除全部
- A2597 Brivanib (BMS-540215)中文名: 布立尼布Target: VEGFR|FGFR|Flk1Summary: VEGFR-2的ATP竞争性抑制剂
- A2168 Dovitinib (TKI-258, CHIR-258)2 Citation中文名: 多韦替尼Target: FLT3|VEGFR|PDGFR|c-Kit|FGFRSummary: 多靶点RTK抑制剂
- A8253 PD 173074Target: VEGFR|FGFRSummary: FGFR抑制剂
- A8252 Nintedanib (BIBF 1120)3 Citation中文名: 尼达尼布Target: VEGFR|PDGFR|FGFRSummary: VEGFR/PDGFR/FGFR抑制剂
- A3870 TG 100801Target: VEGFR|FGFR|Src|Fyn kinaseSummary: 多激酶抑制剂
- A3843 SU 5402Target: VEGFR|PDGFR|FGFRSummary: VEGFR2/FGFR/PDGFR/EGFR抑制剂
- A3626 ML-7 hydrochlorideTarget: Myosin light chain kinases (MLCKs)Summary: 肌球蛋白轻链激酶抑制剂
- A4170 EPZ004777Target: DOT1LSummary: DOT1L抑制剂
- A4122 PHA-680632Target: Aurora Kinases|PLK|FGFRSummary: Aurora激酶抑制剂
- A4166 EPZ56761 CitationTarget: DOT1LSummary: DOT1L抑制剂